Publications
Detailed Information
Who will benefit more from low-dose alteplase in acute ischemic stroke?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Xia | - |
dc.contributor.author | Lee, Keon-Joo | - |
dc.contributor.author | Moullaali, Tom J. | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.contributor.author | Li, Qiang | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.contributor.author | Carcel, Cheryl | - |
dc.contributor.author | Delcourt, Candice | - |
dc.contributor.author | Arima, Hisatomi | - |
dc.contributor.author | Sato, Shoichiro | - |
dc.contributor.author | Robinson, Thompson G. | - |
dc.contributor.author | Song, Lili | - |
dc.contributor.author | Chen, Guofang | - |
dc.contributor.author | Yang, Jie | - |
dc.contributor.author | Chalmers, John | - |
dc.contributor.author | Anderson, Craig S. | - |
dc.contributor.author | Lindley, Richard | - |
dc.contributor.author | Woodward, Mark | - |
dc.date.accessioned | 2024-08-08T01:27:56Z | - |
dc.date.available | 2024-08-08T01:27:56Z | - |
dc.date.created | 2020-05-20 | - |
dc.date.created | 2020-05-20 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.citation | International Journal of Stroke, Vol.15 No.1, pp.39-45 | - |
dc.identifier.issn | 1747-4930 | - |
dc.identifier.uri | https://hdl.handle.net/10371/206074 | - |
dc.description.abstract | Objectives Controversy persists over the benefits of low-dose versus standard-dose intravenous alteplase for the treatment of acute ischemic stroke. We sought to determine individual patient factors that contribute to the risk-benefit balance of low-dose alteplase treatment. Methods Observational study using data from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED), an international, randomized, open-label, blinded-endpoint trial that assessed low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase in acute ischemic stroke patients. Logistic regression models were used to estimate the benefit of good functional outcome (scores 0 or 1 on the modified Rankin scale at 90 days) and risk (symptomatic intracerebral hemorrhage), under both regimens for individual patients. The net advantage for low-dose, relative to standard-dose, alteplase was calculated by dividing excess benefit by excess risk according to a combination of patient characteristics. The algorithms were externally validated in a nationwide acute stroke registry database in South Korea. Results Patients with an estimated net advantage from low-dose alteplase, compared with without, were younger (mean age of 66 vs. 75 years), had lower systolic blood pressure (148 vs. 160 mm Hg), lower National Institute of Health Stroke Scale score (median of 8 vs. 16), and no atrial fibrillation (10.3% vs. 97.4%), diabetes mellitus (19.2% vs. 22.4%), or premorbid symptoms (defined by modified Rankin scale = 1) (16.3% vs. 37.8%). Conclusion Use of low-dose alteplase may be preferable in acute ischemic stroke patients with a combination of favorable characteristics, including younger age, lower systolic blood pressure, mild neurological impairment, and no atrial fibrillation, diabetes mellitus, or premorbid symptoms. | - |
dc.language | 영어 | - |
dc.publisher | Blackwell | - |
dc.title | Who will benefit more from low-dose alteplase in acute ischemic stroke? | - |
dc.type | Article | - |
dc.identifier.doi | 10.1177/1747493019858775 | - |
dc.citation.journaltitle | International Journal of Stroke | - |
dc.identifier.wosid | 000511002800007 | - |
dc.identifier.scopusid | 2-s2.0-85068240956 | - |
dc.citation.endpage | 45 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 39 | - |
dc.citation.volume | 15 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bae, Hee-Joon | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | HEALTH-CARE PROFESSIONALS | - |
dc.subject.keywordPlus | ENHANCED CONTROL | - |
dc.subject.keywordPlus | INTRAVENOUS THROMBOLYSIS | - |
dc.subject.keywordPlus | SAFE IMPLEMENTATION | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
dc.subject.keywordPlus | ENCHANTED TRIAL | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | 0.6 MG/KG | - |
dc.subject.keywordPlus | HYPERTENSION | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordAuthor | Acute stroke therapy | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | ischemic stroke | - |
dc.subject.keywordAuthor | rtPA | - |
dc.subject.keywordAuthor | thrombolysis | - |
dc.subject.keywordAuthor | tPA | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.